Bausch Health Companies (NYSE:BHC) Rating Reiterated by Royal Bank of Canada

Bausch Health Companies (NYSE:BHC)‘s stock had its “sector perform” rating restated by analysts at Royal Bank of Canada in a report released on Friday, Benzinga reports. They currently have a $12.00 target price on the stock. Royal Bank of Canada’s target price suggests a potential upside of 36.99% from the company’s current price.

A number of other brokerages have also weighed in on BHC. Jefferies Financial Group cut their target price on shares of Bausch Health Companies from $16.00 to $14.00 and set a “buy” rating for the company in a research report on Tuesday, February 20th. StockNews.com upgraded shares of Bausch Health Companies from a “hold” rating to a “buy” rating in a research report on Wednesday, February 7th.

Bausch Health Companies Stock Performance

BHC opened at $8.76 on Friday. The firm has a market cap of $3.20 billion, a P/E ratio of -5.41 and a beta of 0.85. The firm has a 50-day moving average of $9.23 and a 200 day moving average of $8.14. Bausch Health Companies has a fifty-two week low of $5.57 and a fifty-two week high of $11.46.

Bausch Health Companies (NYSE:BHC) last issued its earnings results on Thursday, February 22nd. The company reported $1.15 earnings per share for the quarter, topping analysts’ consensus estimates of $1.01 by $0.14. The firm had revenue of $2.41 billion during the quarter, compared to analyst estimates of $2.29 billion. Bausch Health Companies had a negative net margin of 6.76% and a positive return on equity of 5,147.48%. The company’s quarterly revenue was up 9.8% on a year-over-year basis. During the same quarter last year, the business earned $1.02 earnings per share. Equities research analysts predict that Bausch Health Companies will post 3.95 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Bausch Health Companies

A number of large investors have recently modified their holdings of BHC. Principal Securities Inc. bought a new position in shares of Bausch Health Companies in the fourth quarter valued at approximately $31,000. Salem Investment Counselors Inc. bought a new position in shares of Bausch Health Companies in the first quarter valued at approximately $32,000. Lazard Asset Management LLC bought a new position in shares of Bausch Health Companies in the second quarter valued at approximately $49,000. Tower Research Capital LLC TRC boosted its position in shares of Bausch Health Companies by 283.1% in the fourth quarter. Tower Research Capital LLC TRC now owns 6,918 shares of the company’s stock valued at $55,000 after acquiring an additional 5,112 shares during the period. Finally, Bfsg LLC bought a new position in shares of Bausch Health Companies in the fourth quarter valued at approximately $63,000. 78.65% of the stock is currently owned by institutional investors.

Bausch Health Companies Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.